Navigation Links
Phase III Randomised Controlled Trial Confirms Clinical Efficacy and Safety of Radioembolisation Using 90Y-resin Microspheres for Patients With Inoperable Colorectal Cancer Liver Metastases That Have Failed Chemotherapy
Date:8/19/2010

ioembolisation plus 5FU (hazard ratio 0.38; p=0.003). The time to progression of disease anywhere in the body was also significantly longer, from a median of 2.1 months in the 5FU control arm to 4.5 months in patients in the radioembolisation/5FU arm (hazard ratio 0.51; p=0.03). Control of liver metastases was also significantly increased in patients receiving radioembolisation plus 5FU, from 35% to 85% (p=0.001). More patients in the 5FU-only control arm experienced severe side effects than those receiving radioembolisation plus 5FU (26% versus 5%; p=0.10).

The ability to show a difference in the overall survival of patients was blunted by the ethical design of the study, since patients receiving 5FU alone were reassessed once their cancer progressed, and, if possible, were treated with radioembolisation alone. Ten patients in the control arm later received radioembolisation and 6 received further chemotherapy, as did 9 patients in the radioembolisation plus 5FU group. Median overall survival was 7.3 months in the patients receiving 5FU alone, compared to 10.0 months in patients receiving radioembolisation plus 5FU, a difference that was not statistically significant.

"The combination of radioembolisation using 90Y-resin microspheres and 5FU chemotherapy was well tolerated and significantly improves the outcomes for patients compared with 5FU alone," said Dr Alain Hendlisz, chief of the gastroenterology unit at Institut Jules Bordet in Brussels, Belgium, and lead investigator of the trial. "The results of this randomised controlled trial provide Level 1 evidence that radioembolisation with 90Y-resin microspheres is a valid therapeutic option for patients with colorectal cancer liver metastases that have failed chemotherapy."

Large international randomised controlled trials are currently evaluating the effectiveness of radioembolisation using 90Y-resin microspheres with first-line chemotherapy in the treatment of patients with colorectal canc
'/>"/>

SOURCE Sirtex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
2. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
3. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
4. New England Journal of Medicine Publishes Data from Pivotal Phase 3 PROVENGE IMPACT Study
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
7. Fulton Project Advances to Phase 2 of Loan Guarantee Process
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. ChemoCentryx Reports Positive Phase I Study Results for CCX354 at the Annual European Congress of Rheumatology (EULAR)
10. PRA International Opens Phase I Unit in Budapest
11. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... (PRWEB) September 22, 2014 This is ... of the M-Phenylenediamine (mPDA) industry in Global and ... industry, including definitions, applications and industry chain structure. Global ... with a focus on history, developments, trends and competitive ... and Chinese situation is also offered. , The report ...
(Date:9/22/2014)... Jose, California (PRWEB) September 22, 2014 ... Chitin and chitosan are natural biopolymers available in ... extracted from easily available resources such as shells ... and chitosan is mainly due to the high ... cellulose. Chitosan finds application in various industries owing ...
(Date:9/22/2014)... Invisible Sentinel Inc., a life-sciences company ... beverage industries, announced today that its first-in-class Veriflow® ... agreement by Enartis, a global provider of specialty ... Group company headquartered in Trecate, Italy, will distribute ... global markets for their own in-winery use in ...
(Date:9/22/2014)... 22, 2014 FierceBiotech today announced its ... biotechnology companies of 2014. FierceBiotech editors John Carroll ... this year’s winners. Those selected are identified as ... the industry. , "It's always a lot ... Fierce 15 companies," said Carroll. "This year in particular ...
Breaking Biology Technology:m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2
... laboratory-quality results in physician,s office -, MADISON, ... of Quest Diagnostics Incorporated (NYSE: DGX ),today ... I T(TM) fecal,immunochemical test, a point-of-care version of ... with the sensitivity and,specificity of the laboratory-based InSure ...
... New imaging modality highlights Volcano commitment to intravascular ... and opens up new clinical and ... May 8 ,Volcano Corporation (Nasdaq: VOLC ), ... functional measurement (FM) and Optical,Coherence Tomography (OCT) products ...
... When pharmaceutical and,biotech chemistry sourcing management gathers in ... Pharma ChemOutsourcing Conference & Exhibition,areas of special interest ... discussion will center on Asian,suppliers, rising prices and ... in China to tighten quality control and protect ...
Cached Biology Technology:Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 2Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 3Volcano Corp Announces First Human Use of the Volcano Optical Coherence Tomography (OCT) Imaging Catheter 4API and Raw Material Supply Concerns Focal Point of Pharma ChemOutsourcing Conference September 8-9 in New Jersey 2
(Date:9/21/2014)... cowpea (black-eyed peas) is a fascinating example of how ... is the story of the scientist behind the research. ... of the 21st Century to serve as an accessible ... was recently published by the Crop Science Society of ... (IITA). , Singh has devoted his life,s work to ...
(Date:9/21/2014)... strains of bacteria have emerged that resist even the ... forms of tuberculosis and staphylococcus, infect more than 2 ... the urgent need for new treatments, scientists have discovered ... decade. , MIT engineers have now turned a powerful ... that can disable any target gene, they have shown ...
(Date:9/21/2014)... protein therapy that disrupts the process that causes cancer ... through the blood stream and start aggressive new growths ... metastasis, can cause cancer to spread with deadly effect. ... cancer fall prey to metastatic forms of the disease," ... describes a new therapeutic approach in Nature Chemical ...
Breaking Biology News(10 mins):Battling superbugs 2Battling superbugs 3Battling superbugs 4Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... arrests the growth of prostate cancer cells and tumors in ... University of Chicago Medicine. Caffeic acid phenethyl ester, or ... resin used by bees to patch up holes in hives. ... for conditions ranging from sore throats and allergies to burns ...
... understand how plants around the world will act in ... that measure how they respond to artificial warming. But ... potential advances in the timing of flowering and leafing ... a result, species could change far more quickly than ...
... article in F1000 Biology Reports published ... biofuels could meet about 30% of the global demand for ... released into the atmosphere from burning fossil fuels, without having ... that one of the causes of detrimental climate change is ...
Cached Biology News:Beehive extract shows potential as prostate cancer treatment 2Beehive extract shows potential as prostate cancer treatment 3Experiments may understate plant responses to climate 2Experiments may understate plant responses to climate 3Better plants for biofuels 2
... Solid phase reagent for ... Easy & unique water ... with detergents and chaotropes; ... recover non-envelop viruses while ...
PKA Sampler Kit 10 mu g each...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
Protein Tyrosine Phosphatase Sampler Kit 10g each...
Biology Products: